Vertex drug for cystic fibrosis wins approval - STAT News
Bristol Myers Squibb's Sotyktu met primary endpoint in Phase 3 psoriatic arthritis trials. Novo Nordisk's CagriSema fell short of weight loss projections, affecting stock. FDA granted breakthrough status to Neuralink's Blindsight and other devices. Vertex's Alyftrek approved for cystic fibrosis. Eli Lilly's Zepbound approved for sleep apnea, potentially reducing CPAP demand.
Highlighted Terms
Related News
Bristol Myers Squibb's Sotyktu met primary endpoint in Phase 3 psoriatic arthritis trials. Novo Nordisk's CagriSema fell short of weight loss projections, affecting stock. FDA granted breakthrough status to Neuralink's Blindsight and other devices. Vertex's Alyftrek approved for cystic fibrosis. Eli Lilly's Zepbound approved for sleep apnea, potentially reducing CPAP demand.